“Uti Delong has rarely been included in the CSCO Guidelines before being approved.”
It is reported that “Huahao Zhongtian” has recently completed 890 million yuan of E round (Pre-IPO round) financing. This round of financing was jointly led by Yifeng Capital and Matrix Partners China, followed by CCB International, Sinopharm Zhongjin, Tianchuang Capital, and Chengdu Biocity. The funds raised in this round will be used for the continuous development of the company’s product pipeline, the in-depth construction of key technology platforms, the market promotion of the upcoming leading product UTI Delong, the second phase construction of the industrialization base, international multi-center clinical research, and new varieties The introduction and global strategic cooperation.
“Huahao Zhongtian” is engaged in the research and development of natural microbial small molecule anti-tumor innovative drugs. According to the official website information, At present, 1 product of the company is applying for product listing application, 2 varieties have been approved for the national “Major New Drug Creation” major scientific and technological project, and 5 varieties are in the clinical research stage.
Picture from pexels
“Huahao Zhongtian”, a national class 1 new drug, Utiideron (Utidi®), is an epothilone analog synthesized through genetic engineering. The results of previous studies have shown that it has The anti-tumor activity of liver cancer, bowel cancer, prostate cancer and other common tumors is better than paclitaxel, and it also has a good effect on multi-drug resistant tumors of paclitaxel and other chemotherapeutics.
The phase III clinical study of Utidrolone in the treatment of advanced breast cancer shows that compared with the standard regimen, it not only significantly improves the response rate (ORR) and progression-freeSurvival period (PFS), and can significantly improve the overall survival (OS) of patients with advanced breast cancer.The results of this study were rated as the 2016 ASCO Major Research Progress. Uti Delong is expected to be approved for listing in the near future.
In addition, the “Huahao Zhongtian” product pipeline also includes the development of other solid tumor indications for Utidro, the oral dosage form of Utidro, and series such as ONCO-1, BG18, BG44, BGM57, BGMT8 and BGLP1. National Class 1 new anti-tumor drugs with different targets and mechanisms of action.
This round of investor Yifeng Capital Chairman Zhu Jinqiao said that epothilone compounds, as a new type of tubulin stabilizer, have always been a hot spot for the research and development of chemotherapeutics of foreign major pharmaceutical companies. “Huahaozhongtian”‘s new epothilone drug Utidro has shown clinical benefits in patients with lung cancer, bowel cancer and other solid tumors. It is expected to replace paclitaxel in the future and become a new mainstream chemotherapy drug strong>, the market potential is considerable.
Edit: Cai Shuning